An ka furakɛli laɲinitaw dɔn sinji kansɛri furakɛli kan.

"Kansɛri" daɲɛ bɛ siran an bɛɛ ɲɛ dɔɔnin, ɔnhɔn? Nka furakɛli dɔnniya ɲɛtaa fɛ, fɛɛrɛ kura ni ɲɛtaa caman bɔra kansɛri kɛlɛli la. Bi, an bɛna kuma o furakɛli fɛɛrɛ ɲuman dɔ kan, min bɛ fɔ kosɛbɛ, kɛrɛnkɛrɛnnenya la sinji kansɛri la. o bɛ wele ko furakɛli laɲinitaw . An k’a lajɛ a ye min ye, a bɛ baara kɛ cogo min na, ani i ka kan ka min dɔn o ko la.

N’an y’a fɔ cogo nɔgɔman na, furakɛli kuntaalajan ye mun ye?

Miiri k’a filɛ, chimiothérapie, i n’a fɔ an b’a dɔn cogo min na tuma caman na, o bɛ farikolokisɛw tiɲɛ minnu bɛ tila teliya la. O tɛ se ka kansɛribanakisɛw dɔrɔn tiɲɛ, nka a bɛ se ka farikolokisɛ kɛnɛmanw fana tiɲɛ. O de kama a ka ca a la, chimiothérapie bɛ kɔlɔlɔw lase mɔgɔ ma i n’a fɔ kunsigi bɔli ani kɔnɔboli.

Nka nin furakɛli fɛɛrɛ in min bɛ wele ko Targeted Therapy, o ni o tɛ kelen ye kosɛbɛ. Ni an b’a fɛ ka tiɲɛ fɔ, nin ye furakɛli ‘hakilitigi’ ye kosɛbɛ. a bɛ kansɛribanakisɛw dɔrɔn de laɲini ani ka bin u kan . Nin furakɛli fɛɛrɛ in bɛ baara kɛ ni an farikolo yɛrɛ ka farikolo tangalanw ye walasa ka kansɛribanakisɛw tiɲɛ, walima ka taamasiɲɛw bali, kansɛribanakisɛw mago bɛ minnu na walasa u ka bonya. O bɛ tiɲɛni dɔgɔya kosɛbɛ farikolokisɛ kɛnɛmanw na. O nafa ye ko a ka ca a la a kɔlɔlɔw ka dɔgɔn ka tɛmɛ chimiothérapie kan.

Nin furakɛli in bɛ baara kɛ cogoba fila la:

1. Banakisɛfagalanw tali : Nin farikolo tangalanw bɛ sɔrɔ farikolokisɛ kɛrɛnkɛrɛnnenw fɛ minnu bɛ an farikolo tangalanw na. O banakisɛfagalanw bɛ dilan ni fɛn dilannenw ye laboratuwari kɔnɔ ka di farikolo ma i n’a fɔ fura. Olu bɛ nɔrɔ kansɛribanakisɛw la ka u bali ka bonya walima k’u tiɲɛ.

2. Fura misɛnniw: Olu ye furaw ye minnu bɛ se ka ta i n’a fɔ furakisɛ. U bɛ baara kɛ ni taamasiɲɛw siraw datuguli ye kansɛribanakisɛw kɔnɔ minnu b’u dɛmɛ ka tila ani ka bonya.

Aw ka dɔgɔtɔrɔ bɛna a dɔn furakɛli laɲinilen suguya min bɛnnen don aw ma ka kɛɲɛ ni sinji kansɛri suguya tigitigi ye min bɛ aw la.

HER2-Positive Breast Cancer ani a furakɛli

Sinna kansɛri bɛ mɔgɔ minnu na, olu 20% ɲɔgɔn, walima mɔgɔ duuru o duuru, kelen ɲɔgɔn, banakisɛ dɔ bɛ u la min bɛ wele ko `HER2`. O fiɲɛ bɛ kɛ sababu ye ka jeninida in kopi caman kɛ. Ni `HER2` farikolojɔlifɛn caman bɛ kansɛribanakisɛw kan, an b'o kansɛri wele ko "HER2-positif barajuru kansɛri."

Ni aw ka kansɛri ye `HER2-positif` ye, furakɛli kɛrɛnkɛrɛnnenw bɛ yen minnu ɲɛsinnen don a ma, minnu bɛ se ka kɛ kosɛbɛ.

• Trastuzumab : 1 .Nin ye furakɛli kunba ye min ɲɛsinnen bɛ kansɛri `HER2-positif` ma. Nin fura in bɛ sɔrɔ tɔgɔ suguya caman na i n’a fɔ `Herceptin`, `Kanjinti`, `Ogivri`. O ye pikiri ye min bɛ kɛ jolisira dɔ la. A bɛ da a la ko a bɛ kansɛri kunbɛn cogo saba la:
• Kansɛribanakisɛw bɛ nɔrɔ a sanfɛla la ka u bali ka bonya.
• A bɛ dɛmɛ don ka kansɛribanakisɛw tiɲɛ ni taamasiɲɛ ye an yɛrɛ ka farikolo tangacogo la.
• Ni a kɛra ni chimiothérapie ye, o bɛ dɔ fara o furakɛli ninnu ɲɛtaa kan .

• Pertuzumab : Nin fura in, n’a tɔgɔ ye ko `Perjeta`, o ye banakisɛfagalan wɛrɛ ye min bɛ di kansɛri `HER2-positif` ma. A ka ca a la, a ni `Trastuzumab` ni chimiothérapie fura `docetaxel` faralen ɲɔgɔn kan. Nka, a man ɲi musokɔnɔma ma, barisa a bɛ se ka kojugu kɛ den kɔnɔbara la.

• Fura wɛrɛw : `Ado-trastuzumab emtansine (Kadcyla), `Margetuximab (Margenza), ani `Fam-trastuzumab deruxtecan-nxki (Enhertu)` fana ye bi furaw ye minnu bɛ di nin kansɛri suguya in ma, kɛrɛnkɛrɛnnenya la ni kansɛri jɛnsɛnna (a taara ɲɛ) walima ni furakɛli wɛrɛw ma ɲɛ.

• Furakisɛw : Lapatinibi (Tykerb) ni Neratinib (Nerlynx) ye furaw ye minnu ɲɛsinnen don kansɛriw ma minnu bɛ sɔrɔ HER2 fɛ , minnu bɛ se ka ta furakisɛw ye. Olu fana ka teli ka di furakɛli wɛrɛw kɔfɛ.

Sinna kansɛri HER2-Negatif furakɛli

Ni aw ka kansɛribanakisɛw tɛ ni `HER2` jamu nafama ye min kofɔra ka tɛmɛ, o kɔrɔ ye ko `HER2` farikolojɔlifɛn caman tɛ yen, o tuma na, o kansɛri bɛ wele ko "HER2-negative breast cancer." O kɔ, furakɛli suguya wɛrɛ bɛna di aw ma.

Fura kɛrɛnkɛrɛnnenw bɛ yen minnu ɲɛsinnen don kansɛri suguya in fana ma.

• Fura minnu bɛ kɛ i n’a fɔ `Everolimus (Afinitor), `Palbociclib (Ibrance),` ani `Ribociclib (Kisqali)` bɛ di ka fara ɔrimɔni furakɛli kan. Olu ye furaw ye minnu bɛ di musow ma, kɛrɛnkɛrɛnnenya la kalolabɔ kɔfɛ, ni kansɛri jɛnsɛnna.
• PARP balilanw : Ni aw ka kansɛri tɛ HER2 sɔrɔ ani ni BRCA jamu jiginni bɛ aw la, fura suguya kɛrɛnkɛrɛnnen dɔ bɛ se ka di aw ma min bɛ wele ko PARP balilanw, i n’a fɔ Olaparib (Lynparza) ani Talazoparib (Talzenna). Olu fana ye furakɛli laɲinitaw ye minnu bɛ kansɛribanakisɛw laɲini kɛrɛnkɛrɛnnenya la.

A kɔlɔlɔ jumɛnw ka teli ka sɔrɔ?

I n’a fɔ a fɔra cogo min na ka tɛmɛ, hali ni kɔlɔlɔw ka dɔgɔn ka tɛmɛ chimiothérapie kan, furakɛli laɲinitaw bɛ se ka kɔlɔlɔ dɔw lase mɔgɔ ma hali bi. Olu tɛ kelen ye furaw ni furaw cɛ. ni kɔlɔlɔ dɔw ye aw sɔrɔ , aw bɛ o fɔ aw ka dɔgɔtɔrɔ ye o yɔrɔnin bɛɛ . Tuma caman na, u bɛ se ka kunbɛn.

Kɔrɔtɔko dɔ bɛ se ka dɔn cogo di?

Ni aw ye nin taamasiɲɛ ninnu dɔ walima caman sɔrɔ, o bɛ se ka kɛ kɔrɔtɔko ye. I kana i ɲɛmajɔ u la abada. Aw bɛ dɔgɔtɔrɔ wele joona. Ni aw tɛ se ka se a ma, aw bɛ taa dɔgɔtɔrɔso la min ka surun aw la, o ka kɔrɔtɔko ɲɛmɔgɔso (ETU) .